Key Points
- Insider sale: John Patrick Shannon Jr. sold 23,242 shares on November 13 at an average price of $7.46 for total proceeds of $173,385.32, leaving him with 2,643,153 shares (a 0.87% reduction in his position).
- Analyst sentiment: The stock carries a consensus rating of “Moderate Buy” with an average target price of $9.58 (five Buys, two Holds, one Sell).
- Stock snapshot: Xeris has a market capitalization of about $1.2 billion, a negative P/E of -72.59, a 52-week range of $2.82–$10.08, and recent trading around $7.26 (stock up ~1.1% on the day).
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 23,242 shares of the business's stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $7.46, for a total value of $173,385.32. Following the sale, the insider owned 2,643,153 shares of the company's stock, valued at approximately $19,717,921.38. The trade was a 0.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Xeris Biopharma Stock Up 1.1%
Shares of XERS opened at $7.26 on Tuesday. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -72.59 and a beta of 0.21. Xeris Biopharma Holdings, Inc. has a 52-week low of $2.82 and a 52-week high of $10.08. The stock has a 50 day moving average price of $8.34 and a 200 day moving average price of $6.53.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Leerink Partners upped their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the company an "outperform" rating in a research note on Tuesday, August 19th. Oppenheimer reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Zacks Research downgraded Xeris Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, October 30th. Finally, Piper Sandler upped their target price on Xeris Biopharma from $6.00 to $8.00 and gave the company a "neutral" rating in a research report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $9.58.
Get Our Latest Stock Report on Xeris Biopharma
Institutional Investors Weigh In On Xeris Biopharma
A number of institutional investors and hedge funds have recently made changes to their positions in XERS. AlphaQuest LLC acquired a new stake in shares of Xeris Biopharma during the third quarter worth about $35,000. Xponance Inc. purchased a new stake in Xeris Biopharma during the 1st quarter valued at approximately $57,000. FORA Capital LLC purchased a new stake in Xeris Biopharma during the 1st quarter valued at approximately $60,000. Northwestern Mutual Wealth Management Co. lifted its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company's stock worth $63,000 after acquiring an additional 5,000 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $68,000. 42.75% of the stock is owned by hedge funds and other institutional investors.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
